How deadly is Prostate cancer?

Sepira mbebayani kanker prostat?

Kanker prostat minangka kanker paling umum nomer loro ing pria ing saindenging jagad, kanthi kira-kira 1,276 yuta kasus anyar sing dilaporake ing taun 2018, sing makili 7,1% kabeh kasus kanker ing pria.

Tingkat kematian kanggo kanker prostat uga dhuwur, kanthi kira-kira 37.005 kematian ing saindenging jagad ing taun 2018.

Nanging, tingkat mortalitas beda-beda miturut wilayah, kanthi Afrika Kulon duwe risiko kaping lima paling dhuwur kanggo mortalitas kanker prostat ing saindenging jagad, lan Nigeria duwe populasi lan ekonomi paling gedhe ing wilayah iki.

Ing Nigeria, kanker prostat minangka kanker sing paling umum lan paling mematikan kanggo pria, kanthi kira-kira 32,8 kasus lan 16,3 kematian saben 100.000 pria.

Iki luwih saka kaping pindho tingkat pati ing Amerika Utara.

Deteksi penyakit sing telat, sumber daya sing winates kanggo skrining lan deteksi, lan nyuda dokumentasi lan nglaporake kasus nyumbang kanggo tingkat mortalitas sing dhuwur ing Nigeria.

Ing Amerika Serikat, kanker prostat minangka panyebab kanker sing paling umum nomer loro ing wong lanang, kanthi udakara 40.0000 wong lanang sing tilar donya amarga penyakit kasebut saben taun.

Tingkat kematian kanker prostat wis alon-alon mudhun wiwit wiwitan taun 1990-an, nanging tetep dadi masalah kesehatan sing signifikan.

Sakabèhé, kanker prostat minangka penyakit sing mbebayani, utamane ing wilayah sing duwe akses terbatas kanggo perawatan medis lan sumber daya skrining.

Nanging, deteksi lan perawatan awal bisa nambah asil kanthi signifikan lan nyuda tingkat mortalitas.

Referensi-referensi

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.

Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.

Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.

Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.

Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.

Penafian: medis

Situs web iki diwenehake mung kanggo tujuan pendhidhikan lan informasi lan ora dadi menehi saran medis utawa layanan profesional.

Informasi sing diwenehake ora kudu digunakake kanggo diagnosa utawa ngobati masalah utawa penyakit kesehatan, lan wong-wong sing golek saran medis pribadi kudu takon karo dokter sing duwe lisensi.

Mangga dicathet jaringan saraf sing ngasilake wangsulan kanggo pitakonan, utamané ora akurat nalika nerangake konten numerik. Contone, jumlah wong sing didiagnosis karo penyakit tartamtu.

Tansah golek saran saka dhokter utawa panyedhiya kesehatan sing berkualitas liyane babagan kahanan medis. Aja ora nggatekake saran medis profesional utawa telat nggoleki amarga apa sing wis diwaca ing situs web iki. Yen sampeyan mikir sampeyan bisa duwe darurat medis, nelpon 911 utawa pindhah menyang kamar darurat paling cedhak langsung. Ora ana hubungan dokter-pasien sing digawe dening situs web iki utawa panggunaan. Ora BioMedLib utawa karyawan, utawa kontributor situs web iki, nggawe perwakilan, ekspres utawa tersirat, babagan informasi sing diwenehake ing kene utawa panggunaan.

Penafian: hak cipta

Undhang-undhang Hak Cipta Milenium Digital taun 1998, 17 U.S.C. § 512 ( DMCA) nyedhiyakake recourse kanggo pamilik hak cipta sing percaya yen materi sing katon ing Internet nglanggar hak-hak miturut hukum hak cipta AS.

Yen sampeyan percaya kanthi tulus manawa konten utawa materi sing kasedhiya gegayutan karo situs web utawa layanan kita nglanggar hak cipta sampeyan, sampeyan (utawa agen sampeyan) bisa ngirim kabar kanggo njaluk supaya konten utawa materi kasebut dicopot, utawa akses diblokir.

Kabar kudu dikirim kanthi nulis liwat email (deleng bagean "Kontak" kanggo alamat email).

DMCA mbutuhake kabar sampeyan babagan pelanggaran hak cipta sing diduga kalebu informasi ing ngisor iki: (1) deskripsi karya hak cipta sing dadi subyek pelanggaran sing diduga; (2) deskripsi konten sing diduga nglanggar lan informasi sing cukup kanggo ngidini kita nemokake konten kasebut; (3) informasi kontak kanggo sampeyan, kalebu alamat, nomer telpon lan alamat email; (4) pernyataan dening sampeyan yen sampeyan duwe kapercayan sing apik yen konten kanthi cara sing dikritik ora diidini dening pemilik hak cipta, utawa agen, utawa dening operasi hukum apa wae;

(5) pratelan dening sampeyan, ditandatangani kanthi paukuman sumpah palsu, manawa informasi ing pemberitahuan kasebut akurat lan sampeyan duwe wewenang kanggo ngetrapake hak cipta sing diklaim dilanggar;

lan (6) tandha tangan fisik utawa elektronik saka pemilik hak cipta utawa wong sing sah tumindak atas jenenge pemilik hak cipta.

Ora kalebu kabeh informasi ing ndhuwur bisa nyebabake wektu tundha kanggo ngolah keluhan sampeyan.

Kontak karo

Mangga ngirim kita email karo sembarang pitakonan / saran.

How deadly is prostate cancer?

Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.

The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.

However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.

In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.

This is more than double the death rate in North America.

Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.

In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.

The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.

Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.

However, early detection and treatment can significantly improve outcomes and reduce mortality rates.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.